

CIRM Funded Clinical Trials

A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

Disease Area:	Brain Cancer
Investigator:	Anthony Gringeri
Institution:	ImmunoCellular Therapeutics
CIRM Grant:	CLIN2-08280 (Closed)
Award Value:	\$5,391,016
Trial Sponsor:	ImmunoCellular Therapeutics
Trial Stage:	Phase 3
Trial Status:	Suspended
Targeted Enrollment:	414
ClinicalTrials.gov ID:	NCT02546102

Details:

ImmunoCellular Therapeutics is targeting six proteins that are found on the surface of cancer stem cells in glioblastoma, a brain cancer. Immune cells from the patient's own immune system are exposed to fragments of these cancer cell proteins in the lab. When returned to the patient's body, these immune system cells can now help the patient's immune system identify, and then hopefully kill, the cancer stem cells responsible for the tumor's recurrence and growth. This Phase 3 trial was suspended in June 2017 due to lack of sufficient financial resources.

Design:

Randomized, double-blind study.

Goal:

Registration-enabling Phase 3 trial. Safety. Efficacy - overall survival.

Updates:

This study has suspended participant recruitment.